Increased bioavailability of oral melatonin after fluvoxamine coadministration

被引:75
作者
Härtter, S [1 ]
Grözinger, M [1 ]
Weigmann, H [1 ]
Röschke, J [1 ]
Hiemke, C [1 ]
机构
[1] Univ Mainz, Neurochem Lab, Dept Psychiat, D-55131 Mainz, Germany
关键词
D O I
10.1067/mcp.2000.104071
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Fluvoxamine, a selective serotonin reuptake inhibitor, is known to elevate melatonin serum concentrations. It has not been clear whether these effects might be attributed to an increased melatonin production or to an decreased elimination of melatonin, The latter hypothesis was tested by this study. Methods: Five healthy male volunteers (one CYP2D6 poor metabolizer) received 5 mg melatonin either with or without coadministration of 50 mg fluvoxamine, Serum concentrations of melatonin and fluvoxamine were assessed from 0 to 28 hours after melatonin intake. Results: Coadministration of fluvoxamine, on average, led to an 17-fold higher (P < .05) area under concentration-time curve (AUC) and a 12-fold higher (P < .01) serum peak concentration (C-max) of melatonin. The terminal elimination half-life was not significantly affected. The AUC and C-max of fluvoxamine were about three times higher and the half-life was about two times higher in the poor metabolizer. There was a correlation (r = 0.63; P < .01:) between the melatonin and fluvoxamine serum concentrations. The poor metabolizer was found to have: a more pronounced and longer-lasting effect of fluvoxamine on the pharmacokinetics of melatonin, Conclusion: This study showed an increase in the bioavailability of oral melatonin by coadministration of fluvoxamine. The effects of fluvoxamine on the melatonin serum concentrations in patients with depression might therefore be caused by inhibition of the elimination of melatonin and not attributable to an increased production of melatonin.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 34 条
[1]   CLINICAL PERSPECTIVES FOR MELATONIN AND ITS AGONISTS [J].
ARENDT, J .
BIOLOGICAL PSYCHIATRY, 1994, 35 (01) :1-2
[2]   FLUVOXAMINE IS A POTENT INHIBITOR OF CYTOCHROME-P4501A2 [J].
BROSEN, K ;
SKJELBO, E ;
RASMUSSEN, BB ;
POULSEN, HE ;
LOFT, S .
BIOCHEMICAL PHARMACOLOGY, 1993, 45 (06) :1211-1214
[3]   IMMUNOMODULATORY ROLE OF MELATONIN - SPECIFIC BINDING-SITES IN HUMAN AND RODENT LYMPHOID-CELLS [J].
CALVO, JR ;
RAFIIELIDRISSI, M ;
POZO, D ;
GUERRERO, JM .
JOURNAL OF PINEAL RESEARCH, 1995, 18 (03) :119-126
[4]  
CARILLO JA, 1996, CLIN PHARMACOL THER, V60, P183
[5]   THE INFLUENCE OF ACUTE AND SUBCHRONIC ADMINISTRATION OF VARIOUS ANTIDEPRESSANTS ON EARLY MORNING MELATONIN PLASMA-LEVELS IN HEALTHY-SUBJECTS - INCREASES FOLLOWING FLUVOXAMINE [J].
DEMISCH, K ;
DEMISCH, L ;
NICKELSEN, T ;
RIETH, R .
JOURNAL OF NEURAL TRANSMISSION, 1987, 68 (3-4) :257-270
[6]   MELATONIN AND CORTISOL INCREASE AFTER FLUVOXAMINE [J].
DEMISCH, K ;
DEMISCH, L ;
BOCHNIK, HJ ;
NICKELSEN, T ;
ALTHOFF, PH ;
SCHOFFLING, K ;
RIETH, R .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 22 (05) :620-622
[7]  
FALKSON G, 1990, ONCOLOGY-BASEL, V47, P401
[8]   DISTINCT MODES OF MELATONIN SECRETION IN NORMAL MEN [J].
FOLLENIUS, M ;
WEIBEL, L ;
BRANDENBERGER, G .
JOURNAL OF PINEAL RESEARCH, 1995, 18 (03) :135-140
[9]  
FRAZER A, 1986, J NEURAL TRANSM, P269
[10]  
HARTTER S, 1992, CLIN CHEM, V38, P2082